MONISTAT® cures just as effectively
Miconazole, the active ingredient in MONISTAT®, is just as effective at curing vulvovaginal candidiasis (VVC) as fluconazole, the leading prescription pill.1
In a clinical study comparing MONISTAT® to prescription fluconazole, there was no statistically significant difference in clinical cure rates at 14 days post-treatment.1
MONISTAT® relieves symptoms 4x faster*
Systemic fluconazole needs to be digested and absorbed into the bloodstream before it can begin to work. MONISTAT® works at the site of the infection, curing VVC just as effectively as fluconazole while relieving symptoms much sooner.1 See symptom relief study results
MONISTAT® Treats Broad Spectrum of Yeast
MONISTAT® treats the yeast species that cause 99.8% of vaginal yeast infections, more than fluconazole.5,16,18 See species comparison chart
MONISTAT® May Be More Appropriate For Your Pregnant and Diabetic Patients2,7-13†
Even a single, low dose of fluconazole may increase miscarriage risk.7 Fluconazole also may increase the risk of serious hypoglycemic episodes for women on certain antidiabetic drugs.11-13 MONISTAT® 7 meets the CDC Guidelines for treating VVC in pregnant women and treating non-albicans VVC in women with diabetes.2‡ See CDC Guidelines
*Based on a clinical study with MONISTAT® 1 Combination Pack Ovule® treatment vs the leading prescription product
†2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of VVC in pregnant women.
‡Per 2015 CDC Guidelines, options for first-line therapy of non-albicans VVC include longer duration therapy (7-14 days) with a non-fluconazole azole regimen.